Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
|13/10/2015||02/11/2015||Full Pharmacoeconomic Evaluation Recommended|
|04/01/2016||06/06/2017||Reimbursement Not Recommended|
Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.
|The HSE has re-commissioned a full HTA for this product as of 20th March 2018|
|Full pharmacoeconomic assessment re-commissioned by HSE||20/03/2018|
|Pre-submission consultation with Applicant||08/10/2018|
|Submission received from Applicant||27/02/2019|
|Current status||HTA assessment ongoing|